MET and cancer: Dysregulated HGF-c-Met activation is observed in a wide range of malignant tumors (Di Renzo et al., 1995b; Fukuura et al., 1998; Lengyel et al., 2005; Porta et al., 2013; Cao et al., 2015; Lam et al., 2016).